ZA200007019B - Use of prostaglandin agonists to treat erectile dysfunction or impotence. - Google Patents
Use of prostaglandin agonists to treat erectile dysfunction or impotence.Info
- Publication number
- ZA200007019B ZA200007019B ZA200007019A ZA200007019A ZA200007019B ZA 200007019 B ZA200007019 B ZA 200007019B ZA 200007019 A ZA200007019 A ZA 200007019A ZA 200007019 A ZA200007019 A ZA 200007019A ZA 200007019 B ZA200007019 B ZA 200007019B
- Authority
- ZA
- South Africa
- Prior art keywords
- impotence
- erectile dysfunction
- treat erectile
- prostaglandin agonists
- prostaglandin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16851999P | 1999-12-02 | 1999-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200007019B true ZA200007019B (en) | 2002-05-29 |
Family
ID=22611826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200007019A ZA200007019B (en) | 1999-12-02 | 2000-11-29 | Use of prostaglandin agonists to treat erectile dysfunction or impotence. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1108426A3 (enExample) |
| JP (1) | JP2001163779A (enExample) |
| KR (1) | KR20010062061A (enExample) |
| AU (1) | AU7193400A (enExample) |
| CA (1) | CA2327164A1 (enExample) |
| CO (1) | CO5271724A1 (enExample) |
| HU (1) | HUP0004780A3 (enExample) |
| IL (1) | IL139941A0 (enExample) |
| NZ (1) | NZ508560A (enExample) |
| PE (1) | PE20010941A1 (enExample) |
| ZA (1) | ZA200007019B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
| GR1003199B (el) | 1998-08-14 | 1999-09-01 | Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες | |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20070270489A1 (en) | 2003-07-25 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | Remedy for Cartilage-Related Diseases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| BRPI0605926A2 (pt) | 2005-01-14 | 2009-05-26 | Allergan Inc | ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos |
| US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
| US7429669B2 (en) | 2006-06-20 | 2008-09-30 | Allergan, Inc. | Therapeutic compounds |
| EP2069295B1 (en) * | 2006-07-10 | 2013-12-18 | Allergan, Inc. | Substituted cyclopentane derivatives as therapeutic agents |
| BRPI0714683A2 (pt) | 2006-07-28 | 2013-03-26 | Pfizer Prod Inc | agonistas ep2 |
| US9591935B2 (en) | 2007-07-03 | 2017-03-14 | Allergen, Inc. | Therapeutic substituted cyclopentanes |
| AU2009246573B2 (en) | 2008-05-15 | 2014-04-24 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| IN2014CN02290A (enExample) | 2011-09-27 | 2015-06-19 | Reddys Lab Ltd Dr |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| SE9702681D0 (sv) * | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
-
2000
- 2000-11-27 IL IL13994100A patent/IL139941A0/xx unknown
- 2000-11-27 EP EP00310511A patent/EP1108426A3/en not_active Withdrawn
- 2000-11-29 ZA ZA200007019A patent/ZA200007019B/xx unknown
- 2000-11-30 JP JP2000364643A patent/JP2001163779A/ja active Pending
- 2000-11-30 AU AU71934/00A patent/AU7193400A/en not_active Abandoned
- 2000-11-30 PE PE2000001279A patent/PE20010941A1/es not_active Application Discontinuation
- 2000-11-30 CA CA002327164A patent/CA2327164A1/en not_active Abandoned
- 2000-12-01 HU HU0004780A patent/HUP0004780A3/hu unknown
- 2000-12-01 NZ NZ508560A patent/NZ508560A/xx unknown
- 2000-12-01 KR KR1020000072390A patent/KR20010062061A/ko not_active Ceased
- 2000-12-04 CO CO00092096A patent/CO5271724A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001163779A (ja) | 2001-06-19 |
| AU7193400A (en) | 2001-06-07 |
| KR20010062061A (ko) | 2001-07-07 |
| HU0004780D0 (enExample) | 2001-02-28 |
| CO5271724A1 (es) | 2003-04-30 |
| EP1108426A2 (en) | 2001-06-20 |
| HUP0004780A3 (en) | 2004-06-28 |
| HUP0004780A2 (hu) | 2002-04-29 |
| CA2327164A1 (en) | 2001-06-02 |
| NZ508560A (en) | 2002-11-26 |
| PE20010941A1 (es) | 2001-09-24 |
| IL139941A0 (en) | 2002-02-10 |
| EP1108426A3 (en) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200007019B (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence. | |
| PL343794A1 (en) | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction | |
| GC0000096A (en) | Treatment of female sexual dysfunction. | |
| EP1027054A4 (en) | LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION | |
| IL151646A0 (en) | Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction | |
| FI972205A7 (fi) | cGmp-PDE:n estäjiä erektiohäiriön hoidossa | |
| AU2001250821A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
| DE69819515D1 (de) | Hydroxy-prostaglandinderivaten zur behandlung der erektilen dysfunktion | |
| AU2001274649A1 (en) | Topical preparation of alprostadil for the treatment of erectile dysfunction | |
| AU6605800A (en) | Melanocortin receptor-3 ligands to treat sexual dysfunction | |
| IL162154A0 (en) | Prostagandin composition for the treatment of erectile dysfunction | |
| WO2002041894A3 (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
| IL154642A0 (en) | Treatment of urinary dysfunction | |
| AU2002246924A8 (en) | Treatment of erectile dysfunction with rho-kinase inhibitors | |
| WO2000002550A3 (en) | Acetylpiperazines for modulating sexual activity | |
| AU7652400A (en) | Novel combination for the treatment of sexual dysfunction | |
| PL362980A1 (en) | Treatment of sexual dysfunction | |
| ZA200203069B (en) | Peptides for treatment of erectile dysfunction. | |
| AU2001237379A1 (en) | Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction | |
| AU6733500A (en) | Agents for ameliorating erectile dysfunction | |
| ZA992793B (en) | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction. | |
| GB0011926D0 (en) | Treatment of sexual dysfunction | |
| ZA200006374B (en) | Compound for the treatment of female sexual dysfunction. | |
| SI1047428T1 (sl) | Uporaba morfolinola za zdravljenje seksualne disfunkcije | |
| SI1173178T1 (sl) | Sestavek, ki obsega apomorfin in seldenafil, in njegova uporaba za zdravljenje erektilne disfunkcije |